HPLC, UHPLC
HPLC/MS used in cancer study
Sep 05 2011
According to a study published by the Journal of Clinical Bioinformatics and undertaken by a team at Tokyo Medical University, LCNEC is a subtype of large cell carcinoma (LCC) that is characterised by neuroendocrine differentiation, a trait shared by SCLC.
For this reason the pre-therapeutic distinction between the two has been problematic, with issues caused in clinical outcome as a result of the confusion.
The team harvest protein from the cancer foci and subjected it to HPLC/MS, with results verified through quantitative analysis.
"We identified four protein candidates preferentially expressed in LCNEC compared with SCLC," the report stated, with all belonging to cancer stem cell markers.
The team claimed that the proteomic approach via formalin fixed paraffin-embedded samples was effective to detect LCNEC, providing a basis for distinction.
Digital Edition
Chromatography Today - Buyers' Guide 2022
October 2023
In This Edition Modern & Practical Applications - Accelerating ADC Development with Mass Spectrometry - Implementing High-Resolution Ion Mobility into Peptide Mapping Workflows Chromatogr...
View all digital editions
Events
Apr 28 2024 Montreal, Quebec, Canada
May 05 2024 Seville, Spain
May 15 2024 Birmingham, UK
May 19 2024 Brno, Czech Republic
May 21 2024 Lagos, Nigeria